Carmot Therapeutics, Inc.
740 Heinz Avenue
20 articles about Carmot Therapeutics, Inc.
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
Carmot Therapeutics, Inc. today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
Carmot Therapeutics, Inc. announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants and a preclinical study in rodent models of type 1 diabetes to support the effects of CT-868 as an adjunct to insulin treatment.
Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes
Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced a $150 million oversubscribed and up-sized Series E financing.
Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA.
Carmot Therapeutics, Inc. today announced its intent to spin off its Chemotype Evolution (CE) discovery platform in the fields of oncology, immunology and inflammation, to a separate and new company, Kimia Therapeutics (Kimia).
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO
Carmot Therapeutics, Inc. announced today an expansion of its Board of Directors and executive leadership team.
Philanthropic Donations and Debt Financings Rake in Cash for Cancer, Alzheimer's and Mental Healt...
7/29/2022Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases
Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators
Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today a $160 million Series D financing.
Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors.
Carmot announced today that it has closed a $15M financing.
12/12/2017Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology.
Under the deal, Carmot will use its lead-identification technology to identify and advance novel drug leads for Parkinson's disease and other disease areas.
Carmot Therapeutics, Inc. Appoints Aetna Wun Trombley, Ph.D. To The Board Of Directors And Elena Viboch As Director Of Business Development And Operations